{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:54Z","timestamp":1793211054606,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lungcan.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T06:33:44Z","timestamp":1664260424000},"page":"116-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach"],"prefix":"10.1016","volume":"173","author":[{"given":"Cl\u00e9mence","family":"Basse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9di","family":"Chabanol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Bonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fromantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.09.012_b0005","unstructured":"IARC. Cancer Incidence, Mortality and Prevalence Worldwide GLOBOCAN 2012. http:\/\/gco.iarc.fr."},{"key":"10.1016\/j.lungcan.2022.09.012_b0010","unstructured":"Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Lung and Bronchus Cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html. Accessed 30 Aug 2015."},{"issue":"6","key":"10.1016\/j.lungcan.2022.09.012_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0b013e318250ed9d","article-title":"Screening for germline EGFR T790M mutations through lung cancer genotyping","volume":"7","author":"Oxnard","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.09.012_b0020","unstructured":"Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. World Health Organization International Agency for Research on Cancer. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx?cancer=lung. Accessed on 07 Sep 2015."},{"key":"10.1016\/j.lungcan.2022.09.012_b0025","unstructured":"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 7.2015). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 30 June, 2015."},{"issue":"2","key":"10.1016\/j.lungcan.2022.09.012_b0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"The Lancet Oncology."},{"issue":"30","key":"10.1016\/j.lungcan.2022.09.012_b0035","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2022.09.012_b0040","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1016\/j.lungcan.2022.09.012_b0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"PanAsian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO ESMO initiative endorsed by JSMO, KSMO, MOS","volume":"30","author":"Wu","year":"2019","journal-title":"SSO and TOS. Ann Oncol"},{"key":"10.1016\/j.lungcan.2022.09.012_b0050","unstructured":"Clinical practice guidelines in oncology: NCCN guidelines for non-small cell lung cancer V.7. https:\/\/ncci.org."},{"issue":"1","key":"10.1016\/j.lungcan.2022.09.012_b0055","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat Commun."},{"issue":"6","key":"10.1016\/j.lungcan.2022.09.012_b0060","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","article-title":"Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance","volume":"5","author":"Minari","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2022.09.012_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"378","author":"JC Soria,Yuichiro Ohe, Johan Vansteenkiste","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2022.09.012_b0070","doi-asserted-by":"crossref","unstructured":"Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.Mol Cancer Ther.2013;12:220\u20139.","DOI":"10.1158\/1535-7163.MCT-12-0620"},{"issue":"10","key":"10.1016\/j.lungcan.2022.09.012_b0075","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.09.012_b0080","first-page":"85","article-title":"Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin Colorectal Cancer."},{"key":"10.1016\/j.lungcan.2022.09.012_b0085","unstructured":"Sabari JK, Catherine A Shu, Keunchil Park, et al. Amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. Presented at the: 2020 World Conference on Lung Cancer; 29 January 2021; IASLC."},{"issue":"1","key":"10.1016\/j.lungcan.2022.09.012_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12885-020-07685-5","article-title":"EFFR Inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function","volume":"21","author":"Joly-Tonetti","year":"2021","journal-title":"BMC Cancer."},{"issue":"9","key":"10.1016\/j.lungcan.2022.09.012_b0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40261-019-00811-7","article-title":"Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer","volume":"39","author":"Annunziata","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.lungcan.2022.09.012_b0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyv207","article-title":"Skin problems and EGFR-Tyrosine kinase inhibitor","volume":"46","author":"Kozuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"5A","key":"10.1016\/j.lungcan.2022.09.012_b0105","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano","year":"2003","journal-title":"Anticancer Res"},{"issue":"11 Suppl 5","key":"10.1016\/j.lungcan.2022.09.012_b0110","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell","year":"2007","journal-title":"Oncol (Williston Park)"},{"issue":"4","key":"10.1016\/j.lungcan.2022.09.012_b0115","doi-asserted-by":"crossref","first-page":"e1004969","DOI":"10.1080\/23723556.2015.1004969","article-title":"Mechanisms underlying skin disorders induced by EGFR inhibitors","volume":"2","author":"Holcmann","year":"2015","journal-title":"Molecular & Cellular Oncology"},{"issue":"28","key":"10.1016\/j.lungcan.2022.09.012_b0120","doi-asserted-by":"crossref","first-page":"26120","DOI":"10.1074\/jbc.M212082200","article-title":"Epidermal Growth Factor as a biologic switch in hair growth cycle","volume":"278","author":"Mak","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.lungcan.2022.09.012_b0125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-Effects of kinase Inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2022.09.012_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clae.2014.08.005","article-title":"Ocular Side Effects and Trichomegaly of Eyelashes induced by erlotinib: A Case Report and Review of the Literature","volume":"38","author":"Celik","year":"2015","journal-title":"Cont Lens Anterior Eye"},{"issue":"4","key":"10.1016\/j.lungcan.2022.09.012_b0135","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaoncol.2015.0702","article-title":"Cabozantinib\u2014Getting Under the Skin of Cutaneous Toxicity","volume":"1","author":"Jayaram","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2022.09.012_b0140","unstructured":"https\/\/ctep.cancer.gov."},{"key":"10.1016\/j.lungcan.2022.09.012_b0145","unstructured":"Kerob et al. Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody. Arch Dermatol 2006 Dec;142(12):1656-7."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2022.09.012_b0150","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1200\/jco.2008.26.15_suppl.15065","article-title":"Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)","volume":"26","author":"Tubb","year":"2008","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.lungcan.2022.09.012_b0155","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3892\/ol.2015.3265","article-title":"Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.lungcan.2022.09.012_b0160","first-page":"1167","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.09.012_b0165","article-title":"Mechanisms of lethal Skin Toxicities induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. Front","volume":"10","author":"LiY","year":"2022","journal-title":"Oncol."},{"key":"10.1016\/j.lungcan.2022.09.012_b0170","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.2147\/OTT.S145613","article-title":"Preventive Effect of Kampo Medicine (Hangeshashin-to, TJ-14) Plus Minocycline Against Afatinib-Induced Diarrhea and Skin Rash in Patients With Non-Small Cell Lung Cancer","volume":"10","author":"Ichiki","year":"2017","journal-title":"Onco Targets Ther"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222006419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:47Z","timestamp":1759237367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222006419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"alternative-id":["S0169500222006419"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}